



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/697,497	10/30/2003	Stephen C. Suffin	CNSR-07141	8061
<div>23535 7590 08/16/2007 MEDLEN &amp; CARROLL, LLP 101 HOWARD STREET SUITE 350 SAN FRANCISCO, CA 94105</div>				
			EXAMINER KIM, JENNIFER M	
			ART UNIT 1617	PAPER NUMBER
			MAIL DATE 08/16/2007	DELIVERY MODE PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

# Office Action Summary

Application No.

10/697,497

Applicant(s)

SUFFIN ET AL.

Examiner

Jennifer Kim

Art Unit

1617

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☒ Responsive to communication(s) filed on July 26, 2007.
- 2a) ☒ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 1-16 is/are pending in the application.
- 4a) Of the above claim(s) 4-16 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-3 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

## Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

## Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                   | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

### **DETAILED ACTION**

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicants' submission filed on July 26, 2007 has been entered.

### **Action Summary**

The rejection of claims 1-3 under 35 U.S.C. 103(a) as being unpatentable over Quessy et al. (US 2002/0147196 A1) further in view of Zakrzewska et al. (#84, PTO-1449), (Journal of Neurology, Neurosurgery, and Psychiatry 1989) is being maintained for the reasons stated in the previous Office Action.

### ***Response to Arguments***

Art Unit: 1617

Applicants' arguments filed July 26, 2007 have been fully considered but they are not persuasive. Applicants argue that Quessy et al. simply lists oxcarbazepine as one of five possible sodium channel blockers but provides no information showing that the combinations of bupropion with either oxcarbazepine or lamotrigine have similar therapeutic benefits. This is not found persuasive because Quessy et al. lists oxcarbazepine along with lamotrigine as useful for the treatment of neuropathic pain. Therefore, it would have been obvious to one of ordinary skill in the art to interchange one compound for the another when specific compounds are taught as having the same analgesic activity and the efficacy of treating neuropathic pain is retained. Applicants argue that The Suffin Declaration provides sufficient evidence to show that oxcarbazepine and lamotrigine does not work as expected by one having ordinary skill in the art because these two drugs do not have similar effects on rEEG multivariable measurements. The Suffin Declaration has been carefully review and considered. However, it is not persuasive because the data showing that oxcarbazepine has an overall rEEG response pattern that is consistent with stimulant drugs which is contrary to lamotrigine having an overall rEEG response pattern that is consistent with depressant drugs do not relate to the treatment of neuropathy, rather, the rEEG response pattern relate to characterize features of brain function underlying a broad range of psychiatric syndromes. In this case, it would have been obvious to one of ordinary skill in the art to modify the composition of Quessy et al. by replacing lamotrigine with oxcarbazepine because Quessy et al. teach that bupropion can be formulated with any one of disclosed sodium channel blockers including oxcarbazepine

Art Unit: 1617

or lamotrigine and because Quessy et al. teach that oxcarbazepine and lamotrigine are equivalents as both having the **analgesic properties** for the **treatment of neuropathic pain** in combination with bupropion. One of ordinary skill in the art would be motivated to make such a modification with oxcarbazepine in order to fulfill the need of a pharmaceutical composition and providing variety for the treatment of neuropathic pain, not only possessing anti-neuralgic properties but also lacking side-effects. Thus, the claims fail to patentably distinguish over the state of the art as represented by the cited references.

### ***Claim Rejections - 35 USC § 103***

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claims 1-3 are rejected under 35 U.S.C. 103(a) as being unpatentable over Quessy et al. (US 2002/0147196 A1) of record further in view of Zakrzewska et al. (#84, PTO-1449), (Journal of Neurology, Neurosurgery, and Psychiatry 1989) of record.

Quessy et al. teach a pharmaceutical composition comprising **bupropion** and sodium channel blockers including **oxcarbazepine and lamotrigine** useful for the

Art Unit: 1617

treatment of **neuropathic pain**. (page 5, claims 1-3). Quessy et al. illustrate the composition comprising **bupropion and lamotrigine** (page 5, Example 3, claim 6). Quessy et al. teach that using the test compound lamotrigine in a pre-clinical experiment, no adverse side effects were observed. ([0038]). Quessy et al. also teach that the composition can be formulated with **mixtures of NE-reuptake inhibitors which exert analgesic activity (analgesics)**. (page 1, [0009], [0010]). Quessy et al. further teach that the composition can be formulated as a **transdermal patch, sterile injectable solution, tablet, capsules, oral liquid or a sterile liquid for injection** and can be formulated with suitable **polymeric** materials. ([0021]-[0027]). Quessy et al. additionally teach that the composition manifests **synergism** in the treatment of neuropathic pain ([0009]). Quessy et al. lastly teach that there is a need for a pharmaceutical composition that can alleviate neuropathic pain or/its symptoms effectively. (page 1, [0004], [0007]).

However, Quessy et al.'s illustrated composition (example 3) uses lamotrigine with bupropion, rather than oxcarbazepine as instantly claimed.

Zakrzewska et al. teach that **oxcarbazepine** possesses **antineuralgic properties**, is effective in the management of intractable **trigeminal neuralgia**, and elicits an **excellent** therapeutic response in **controlling pain without side effects**. (abstract).

It would have been obvious to one of ordinary skill in the art to modify the composition of Quessy et al. by replacing lamotrigine with oxcarbazepine, because Quessy et al. teach that bupropion can be formulated with any one of disclosed sodium

Art Unit: 1617

channel blockers including oxcarbazepine or lamotrigine, and because Quessy et al. teach that oxcarbazepine and lamotrigine are equivalents both having the anti-neuralgic properties for treating neuropathic pain in combination with bupropion. Further, Zakrzewska et al. also teach that oxcarbazepine has no side effects. One of ordinary skill in the art would be motivated to make such a modification with oxcarbazepine in order to fulfill the need of a pharmaceutical composition and providing variety for the treatment of neuropathic pain, not only possessing anti-neuralgic properties but also lacking side-effects as taught by Zakrzewska et al. There is a reasonable expectation of successfully treating neuropathic pain without side effects with a combination of bupropion and oxcarbazepine, the latter well taught by Zakrzewska et al. as possessing excellent anti-neuralgic properties with an excellent therapeutic response in controlling pain. With regard to further combining with a third drug as set forth in claim 2 and the specified formulation as set forth in claim 3, all deemed obvious because Quessy et al. teach that NE-reuptake inhibitors exert analgesic activity (analgesics) and, therefore, can be incorporated in the obvious combination and because the various formulations set forth in claim 3 are taught by Quessy et al. as suitable formulations for the obvious combination. One would have been motivated to further incorporate analgesics in a mixture to the combination in various formulations disclosed by Quessy et al. in order to successfully formulate an ultimate regimen for the treatment of neuropathic pain possessing at least one synergistic effect disclosed by Quessy et al. without a side effect. Absent any evidence to contrary, there would have been a reasonable expectation of successfully improving the anti-neuropathic pain composition of Quessy

Art Unit: 1617

et al. by combining bupropion and oxcarbazepine in order to fulfill the need of a pharmaceutical composition that can alleviate neuropathic pain without as a side effect.

For these reasons the claimed subject matter is deemed to fail to patentably distinguish over the state of the art as represented by the cited references. The claims are therefore properly rejected under 35 U.S.C. 103.

None of the claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer Kim whose telephone number is 571-272-0628. The examiner can normally be reached on Monday through Friday 6:30 am to 3 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic




Application/Control Number: 10/697,497

Page 8

Art Unit: 1617

Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.



Jennifer Kim  
Patent Examiner  
Art Unit 1617

Jmk  
August 13, 2007